The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Abstract
Induced protein degradation by PROTACs has emerged as a promising strategy to target nonenzymatic proteins inside the cell. The aim of this study was to identify Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, as a novel candidate for PROTACs that can be applied in the degradation of the nonenzymatic protein Tau. A peptide PROTAC by recruiting Keap1-Cul3 ubiquitin E3 ligase was developed and applied in the degradation of intracellular Tau. Peptide 1 showed strong in vitro binding with Keap1 and Tau. With proper cell permeability, peptide 1 was found to colocalize with cellular Keap1 and resulted in the coimmunoprecipitation of Tau and Keap1. The results of flow cytometry and western blotting assays showed that peptide 1 can downregulate the intracellular Tau level in both time- and concentration-dependent manner. The application of Keap1 siRNA silencing and the proteasome inhibitor MG132 confirmed that peptide 1 could promote the Keap1-dependent poly-ubiquitination and proteasome-dependent degradation of Tau. The results suggested that using PROTACs to recruit Keap1 to induce the degradation of Tau may show promising character in the treatment of neurodegenerative disease. Besides, our research demonstrated that Keap1 should be a promising E3 ligase adaptor to be used in the design of novel PROTACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, induced turnover of tau by the UPS, and the degradability of tau species, has been demonstrated by a tau–kelch-like ECH-associated protein 1 (KEAP1) chimeric peptide PROTAC molecule188, as well as by a VHL–tau PROTAC189.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“Additionally, multiple groups have described a range of pepTACs that harness SKP1/SCF F-box, VHL, KEAP1 and other E3 ligases to degrade tau or α-synuclein in primary neurons and other cell lines188,193,213”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“A peptide-based PROTAC which recruits the KEAP1 E3 ligase to degrade Tau protein demonstrates the potential of PROTAC technology to treat neurodegenerative disorders such as Alzheimer’s disease [73].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [73]
In the citing paper
“This PROTAC, termed peptide 1, was able to degrade overexpressed GFP-tagged Tau in different cell lines at 20 µM after 6–12 h of treatment times to various degrees.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Recently, a peptide PROTAC was developed that was able to tether Kelch-like ECH-associated protein-1 (Keap1) and Tau into a ternary complex [105].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Generation of the full-length peptide decreased Keap1 affinity tenfold and exhibited affinity towards Tau in the sub-micromolar range.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Proof of concept for hijacking the BTB E3 ligases has been provided by a peptide PROTAC targeting Tau for degradation by KEAP1 (ref. 79 ).”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [79]
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Classification of Intrinsically Disordered Regions and Proteins
van der Lee, R., Buljan, M., Lang, B., Weatheritt, R. J., Daughdrill, G. W., Dunker, A. K., Fuxreiter, M., Gough, J., Gsponer, J., Jones, D. T., et al. (2014) · Chemical Reviews · doi:10.1021/cr400525m · Cited by 2,249
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 815
Self-citationSmall‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Schweers, O., Schönbrunn, E., Marx, A., & Mandelkow�, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51080-8 · Cited by 569
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M. A., Mandal, A., Deshaies, R. J., Sakamoto, K. M., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 507
Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport
Vossel, K. A., Zhang, K., Brodbeck, J., Daub, A. C., Sharma, P., Finkbeiner, S., Cui, B., & Mucke, L. (2010) · Science · doi:10.1126/science.1194653 · Cited by 486
Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Jaźwa, A., Rojo, A. I., Innamorato, N. G., Hesse, M., Fernández‐Ruíz, J., & Cuadrado, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3731 · Cited by 329
Inducible, reversible system for the rapid and complete degradation of proteins in mammalian cells
Holland, A. J., Fachinetti, D., Han, J. S., & Cleveland, D. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216880109 · Cited by 309
Waste disposal—An attractive strategy for cancer therapy
Salami, J., & Crews, C. M. (2017) · Science · doi:10.1126/science.aam7340 · Cited by 279
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
Jiang, Z., Lu, M., Xu, L., Yang, T., Xi, M., Xu, X., Guo, X., Zhang, X., You, Q., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 263
Self-citationSpecific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation
Chu, T.-T., Gao, N., Li, Q.-Q., Chen, P.-G., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., & Li, Y.-M. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.02.016 · Cited by 247
Drugging Undruggable Molecular Cancer Targets
Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 234
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 157
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 151
Mechanistic Basis of Phenothiazine‐Driven Inhibition of Tau Aggregation
Akoury, E., Pickhardt, M., Gajda, M. J., Biernat, J., Mandelkow�, E., & Zweckstetter, M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208290 · Cited by 151
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 143
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 139
Jiang, Z., Lu, M., & You, Q. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00586 · Cited by 128
Self-citationMaccioni, R. B., Rivas, C. I., & Vera, J. C. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03033.x · Cited by 122
Taremi, S. S., Beyer, B. M., Maher, M., Yao, N., Prosise, W. W., Weber, P. C., & Malcolm, B. A. (1998) · Protein Science · doi:10.1002/pro.5560071011 · Cited by 120
Lu, M., Ji, J., Jiang, Y.-L., Chen, Z., Yuan, Z., You, Q., & Jiang, Z. (2016) · Scientific Reports · doi:10.1038/srep26585 · Cited by 112
Self-citationAge-associated oxidative damage to the p62 promoter: implications for Alzheimer disease
Du, Y., Wooten, M. C., Gearing, M., & Wooten, M. W. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.11.003 · Cited by 108
Lee, H., Puppala, D., Choi, E., Swanson, H. I., & Kim, K. (2007) · ChemBioChem · doi:10.1002/cbic.200700438 · Cited by 96
Greasy tags for protein removal
Neklesa, T. K., & Crews, C. M. (2012) · Nature · doi:10.1038/487308a · Cited by 92
Lucas, X., & Ciulli, A. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.015 · Cited by 92
Kirschberg, T. A., VanDeusen, C. L., Rothbard, J. B., Yang, M., & Wender, P. A. (2003) · Organic Letters · doi:10.1021/ol035234c · Cited by 84
Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors
Lu, M.-C., Chen, Z.-Y., Wang, Y.-L., Jiang, Y.-L., Yuan, Z.-W., You, Q.-D., & Jiang, Z.-Y. (2015) · RSC Advances · doi:10.1039/c5ra16262a · Cited by 55
Self-citationLu, M., Yuan, Z., Jiang, Y.-L., Chen, Z., You, Q., & Jiang, Z. (2016) · Molecular BioSystems · doi:10.1039/c6mb00030d · Cited by 35
Self-citationPolar Recognition Group Study of Keap1-Nrf2 Protein–Protein Interaction Inhibitors
Lu, M., Tan, S.-J., Ji, J., Chen, Z., Yuan, Z., You, Q., & Jiang, Z. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00407 · Cited by 35
Self-citationCationic Cell-Penetrating Peptides Are Potent Furin Inhibitors
Ramos‐Molina, B., Lick, A. N., Shirazi, A. N., Oh, D., Tiwari, R. K., El‐Sayed, N. S., Parang, K., & Lindberg, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130417 · Cited by 31
Flagged first, then by citations
Research works printed but not linked: 1
- Lu, 2016, The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update, Med. Res. Rev., 36, 924, 10.1002/med.21396 · DOI
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Targeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 1,035
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
An open-source drug discovery platform enables ultra-large virtual screens
Gorgulla, C., Boeszoermenyi, A., Wang, Z., Fischer, P. D., Coote, P. W., Das, K. M., Malets, Y. S., Radchenko, D. S., Moroz, Y. S., Scott, D. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2117-z · Cited by 677
Metadata
- Authors
- Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- You, Qidong
- Jiang, Zhengyu
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 146
- Pages
- 251-259
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2792069216
- Cited by
- 310
- References
- 45
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 48 · 2023: 47 · 2022: 35 · 2021: 36 · 2020: 37 · 2019: 24 · 2018: 6
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81773581, 81602948, 81773639)
- Natural Science Foundation of Jiangsu Province of China (BK20160746)
- National Major Science and Technology Project of China (2015ZX09101032, 2017ZX09302003, 2017ZX09101-004-003-006)
- Research Innovation Program for College Graduates of Jiangsu Province (KYLX16_1169)
- Priority Academic Program Development of Jiangsu Higher Education Institutions, the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (SKLNMZZCX201611)
- College Students Innovation Project for the R&D of Novel Drugs (J1310032)
- China Postdoctoral Science Foundation funded project (1600010006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, Keap1, tau protein, ubiquitination, proteasomal degradation, protein degradation, neurodegenerative diseases, polyubiquitination
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Dose-Response Relationship, Drug, Humans, Peptides, Structure-Activity Relationship, Tumor Cells, Cultured, Molecular Structure, tau Proteins, Proteasome Endopeptidase Complex, Ubiquitination, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
